![]() As the COVID-19 pandemic continues to have a lesser impact, we are excited about the growth and momentum in our core business, with strength across our 3 business areas - precision diagnostics, anatomic pathology, and pharma services - and momentum in oncology and reproductive health, particularly with the expansion of oncologic carrier screening through Beacon787, also announced today. Ming Hsieh, Chairman of the Board and Chief Executive Officer, said, “2022 was a transitional and transformative year for Fulgent, as we integrated the acquisitions of Inform Diagnostics and CSI Laboratories and acquired the Pharma business. Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. ![]() Repurchased over 1.8 million shares of common stock at an aggregate cost of $74.3 million under the stock repurchase program announced in March 2022ġ) Core Revenue excludes revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue. Non-GAAP income of $179.4 million, or $5.79 per share GAAP income of $143.4 million, or $4.63 per share Repurchased approximately 815,000 shares of common stock at an aggregate cost of $29.1 million under the stock repurchase program announced in March 2022Ĭore Revenue 1 grew 95% year-over-year to $181.5 million Non-GAAP loss of $14.2 million, or $0.48 per shareĬash, cash equivalents, and investments in marketable securities, including investments pending settlement, of $872.0 million as of December 31, 2022 GAAP loss of $23.8 million, or $0.80 per share (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.Ĭore Revenue 1 grew 97% year-over-year to $55.0 million ![]() Full Year 2022 Total Revenue of $619.0 million Q4 Total Revenue of $67.7 millionįull Year 2022 Core Revenue grows 95% year-over-year to $181.5 million Q4 Core Revenue grows 97% year-over-year to $55.0 million
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |